News

Quotient Sciences, the drug development and manufacturing accelerator, announces that it has completed the rebrand of Arcinova, the Alnwick U.K.-based contract development and manufacturing organization (CDMO). Now called Quotient Sciences - Alnwick, the site has significant expertise in drug substance manufacture, isotope labelling, bioanalysis and drug product development, playing a key role in strengthening Quotient’s services portfolio from candidate selection to commercial manufacturing.

In this interview Stuart McDougall, Head of Bioanalytical Services at Quotient Sciences- Alnwick (Northumberland, UK), discusses the technologies used to generate fast, reliable data for drug development and how recently Arcinova has been acquired by Quotient Sciences. He explains what this new partnership means and how Arcinova/Quotient are preparing to address the needs of the future.

Quotient's VP of Drug Development Sciences, Dr Sarah Stevens, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization, in Drug Development & Delivery's Special Feature Report

An interview with Quotient's CEO, Mark Egerton, was featured in the latest 2021 edition of the U.S Pharma and Biopharma Report by Global Business Reports.

Content: Quotient has been recognized with multiple 2021 CRO Leadership Awards, including two Champion Awards. The CRO Leadership Awards recognizes top performing outsourcing organizations in the drug development arena. Quotient received leadership awards in five of the overall six categories.

Quotient Sciences was featured in Drug Development & Delivery's Special Feature article entitled: "Improving Bioavailability & Solubility: Each Molecule Is Unique."